Prelude Capital Management’s NovoCure NVCR Stock Holding History

Prelude Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,471	Closed	-$214K	–	1477
2024 Q2	$214K	Sell	12,471 -19,016	-60%	-$334K	0.01%	971
2024 Q1	$492K	Buy	+31,487	New	+$463K	0.03%	637
2021 Q3	–	Sell	-1,397	Closed	-$310K	–	1937
2021 Q2	$310K	Sell	1,397 -123	-8%	-$23.9K	0.01%	1180
2021 Q1	$201K	Buy	+1,520	New	+$240K	0.01%	1328
2020 Q3	–	Sell	-1,236	Closed	-$98.8K	–	2197
2020 Q2	$73K	Buy	+1,236	New	+$81.3K	﹤0.01%	1043
2019 Q2	–	Sell	-23,403	Closed	-$1.13M	–	2005
2019 Q1	$1.13M	Sell	23,403 -1,812	-7%	-$87.2K	0.06%	300
2018 Q4	$844K	Sell	25,215 -1,154	-4%	-$42.2K	0.06%	353
2018 Q3	$1.38M	Sell	26,369 -265	-1%	-$10.5K	0.08%	283
2018 Q2	$834K	Buy	26,634 +2,121	+9%	+$59K	0.05%	381
2018 Q1	$534K	Sell	24,513 -2,121	-8%	-$45.6K	0.04%	421
2017 Q4	$538K	Buy	26,634 +17,173	+182%	+$331K	0.04%	402
2017 Q3	$188K	Buy	+9,461	New	+$186K	0.02%	674
2016 Q4	–	Sell	-39,483	Closed	-$337K	–	1711
2016 Q3	$337K	Buy	+39,483	New	+$360K	0.04%	399

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Prelude Capital Management's NVCR Position: Q3 2024 in Review

Prelude Capital Management sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 12,471 shares — an estimated $214K sold.

Prelude Capital Management first reported a position in NVCR in Q3 2016 and held it in 13 quarters. The position peaked at $1.38M in Q3 2018. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

Prelude Capital Management reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
Prelude Capital Management sold 12,471 NovoCure shares in Q3 2024, an estimated $214K.
Prelude Capital Management first reported a position in NovoCure in Q3 2016 and held it in 13 quarters.
Prelude Capital Management's NovoCure position peaked at $1.38M in Q3 2018.
224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.